Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Rolontis (eflapegrastim)

HENDERSON, Nev.--(BUSINESS WIRE)--Aug. 6, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news